In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in in Sweden
|
|
- Annabella Thornton
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE BACTERIOLOGY In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in in Sweden T. Norén 1,2, I. Alriksson 2,T.Åkerlund 3, L. G. Burman 3 and M. Unemo 2 1) Department of Infectious Diseases and 2) Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, Örebro and 3) Swedish Institute for Infectious Disease Control, Solna, Sweden Abstract This study investigated the MICs of 17 antimicrobials, for 606 toxigenic clinical isolates of Clostridium difficile collected between 1993 and 2007 in Sweden. Low MIC 90 values were found for metronidazole (0.5 mg/l), vancomycin (1.0 mg/l), teicoplanin (0.125 mg/l), fusidic acid (1.0 mg/l), linezolid (2.0 mg/l), daptomycin (2.0 mg/l) and tigecycline (0.064 mg/l). Three isolates (0.5%) had elevated MICs for vancomycin (4 8 mg/l); however, these isolates originated from the same patient, who was receiving long-term intravenous vancomycin treatment. High-level clindamycin resistant isolates (MIC >256 mg/l) peaked in 1997 with 39 of 95 (41%) and out of these, 36% were also highly resistant to erythromycin. b-lactams such as penicillin V and piperacillin displayed MIC 90 s of 8 and 32 mg/l, respectively, whereas MICs of cefuroxime were >256 mg/l for all isolates. Universal resistance to ciprofloxacin and levofloxacin was found, and resistance to moxifloxacin increased from 4% of isolates in 2004 to 23% in Notably, these moxifloxacin-resistant isolates did not belong to the recent epidemic PCR ribotype 027, but to the pre-existing epidemic type 012 (82%), and these isolates accounted for the majority of isolates that were resistant to clindamycin (70%), tetracycline (84%) and rifampicin (92%) as well. This investigation of susceptibility data on clinical C. difficile isolates showed variations of multiresistance to be due to a specific PCR ribotype 012, emphasizing the importance of genotyping when evaluating emerging resistance over time. Keywords: 027/NAP1, antimicrobial resistance, Clostridium difficile, Clostridium difficile infection, Etest, Sweden Original Submission: 15 June 2009; Revised Submission: 17 August 2009; Accepted: 17 August 2009 Editor: F. Allerberger Article published online: 3 September 2009 Clin Microbiol Infect 2010; 16: /j x Corresponding author and reprint requests: T. Norén, Department of Infectious Diseases, Örebro University Hospital, SE Örebro, Sweden torbjorn.noren@orebroll.se Introduction PCR ribotype 001 in the UK renews this concern [11]. The main purpose of the present study was to obtain a comprehensive overview, including trends in antimicrobial susceptibility or resistance in toxigenic C. difficile isolates collected from primary CDI patients in a well-defined area of central Sweden over 15 years ( ). Clostridium difficile infection (CDI) is increasing in incidence and morbidity, partly owing to the appearance of the C. difficile 027/NAP1 strain, exhibiting moxifloxacin resistance [1,2], and high levels of toxin and spore production [3,4]. Both the suggested epidemic impact of widespread fluoroquinolone use [5] and the decline in therapeutic efficacy of metronidazole [6] have brought more attention to active antimicrobial susceptibility surveillance of clinical C. difficile isolates [7 9]. When recommended therapies are used, in vitro resistance of C. difficile isolates has not yet been associated with treatment failure [10], although the recent increase in the resistant Materials and Methods C. difficile isolates A total of 606 clinical toxigenic C. difficile isolates from primary CDI patients were recovered by sampling the first consecutive 105 toxin-positive isolates obtained during the years 1993, 1997, 1999, 2002, 2004 and 2007 at Örebro University Hospital in Örebro County (which has approximately inhabitants) in Sweden. Both hospital and community isolates were included, and only primary CDI isolates were selected, avoiding recurrences by excluding Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases
2 CMI Norén et al. Antimicrobial resistance of C. difficile in Sweden 1105 individuals with positive laboratory reports 6 months prior to the actual request date. Toxin testing, culture and preservation of isolates were performed as described elsewhere [12]. The 630 primarily frozen toxin-positive faecal samples yielded a total recovery rate of 96% (606 isolates culturepositive for C. difficile). Accordingly, 24 samples five (1993), ten (1997), one (1999), three (2002), three (2004) and two (2007) were either culture-negative (n = 5) or did not yield isolates identified as C. difficile (n = 19) when analysed by colony appearance and agglutination (Microgen Bioproduct Ltd, Camberley, UK). MIC determination Preserved C. difficile isolates from all years were thawed and cultured anaerobically on pre-reduced fastidious anaerobic agar (FAA; Lab M Ltd, Bury, UK) at 37 C for 48 h. Colonies were subsequently suspended in nutrient broth (Oxoid Ltd, Basingstoke, UK) to a turbidity of 4.0, using the McFarland scale, and seeded on IsoSensitest Agar (Oxoid) supplemented with defibrinated horse blood (5%) and 20 mg/l b- nicotinamide adenine dinucleotide (Sigma-Aldrich, Saint Louis, MO, USA). Initially, from 1993 to 1999, PDM agar (AB Biodisk, Solna, Sweden) was used, as recommended by the manufacturer, but parallel use of both agar media in 1999 showed no significant discrepancies, and the new proposed IsoSensitest medium was used from 2002 onwards (data not shown). Etest strips (AB Biodisk) were applied, and this was followed by anaerobic incubation at 37 C for 48 h. C. difficile ATCC 13124, Bacteroides fragilis ATCC and Enterococcus faecalis ATCC were included as quality control strains. Pharmacological breakpoints were used when available, as recommended by EUCAST (European Committee on Antimicrobial Susceptibility Testing, and the Swedish Reference Group for Antibiotics (SRGA, Antimicrobial agents The following 17 antibiotics were tested: metronidazole, vancomycin, teicoplanin, fusidic acid, clindamycin, erythromycin, rifampicin, piperacillin, penicillin V, cefuroxime, ciprofloxacin, levofloxacin, moxifloxacin, daptomycin, linezolid, tigecycline and tetracycline. The more recently introduced antibiotics, i.e. moxifloxacin, levofloxacin, daptomycin, linezolid and tigecycline (and the older but similar tetracycline), were only included in 2004 and Teicoplanin, cefuroxime and penicillin V were not tested in 2004 and (1997), 102 (1999), 37 (2002), 103 (2004) and 102 (2007)) were subjected to additional PCR ribotyping as well as MIC determination. Statistical analysis The Mann Whitney U-test was used when appropriate. Results The MIC distributions for all antimicrobials specified for each year investigated are provided in Tables 1 3, and MIC 50, MIC 90 and geometric means of MICs are given in Table 4. All C. difficile isolates were inhibited by a concentration of 2 mg/l of metronidazole, and all but three isolates (0.5%) also displayed vancomycin MICs of 2 mg/l (Table 1). Of the other therapeutic alternatives, teicoplanin was the most active agent, displaying MICs 0.5 mg/l for all isolates. Fusidic acid also had favourable MICs ( 4 mg/l), except in the case of four isolates (0.7%) identified in 2002 and 2007 (Table 1). For erythromycin, clindamycin and rifampicin, the prevalence of isolates with high-level resistance (MICs >256 mg/l) peaked in 1997 (36%, 41% and 38% of isolates, respectively, Table 2). For rifampicin, the C. difficile isolates were either highly susceptible (MIC <0.016 mg/l, 80% of isolates) or highly resistant (MIC >256 mg/l, the remaining 20% of isolates) (Table 2). The b-lactams penicillin V and piperacillin displayed MIC 90 s of 8 and 32 mg/l, respectively (Table 4). As expected, all C. difficile isolates were resistant to the cephalosporin cefuroxime (>256 mg/l, Table 2). The activity of tetracycline was generally high, with 84% of isolates displaying MICs of 0.25 mg/l, although a doubling of the numbers of highly resistant isolates was observed between 2004 (9.8%) and 2007 (21%). The related antibiotic tigecycline had a very low MIC 90 (0.064 mg/l), and no resistant isolate was found. Similarly, daptomycin and linezolid had relatively low MIC 90 s (Table 4). All isolates tested were highly resistant (MIC >32 mg/l) to ciprofloxacin. This was also the case for levofloxacin; that is, all isolates tested in 2004 and 2007, (Table 3) as well as 49 random isolates collected during , displayed an MIC of >32 mg/l (data not shown). In contrast, only 4% (4/102) of the isolates were moxifloxacin-resistant in 2004, as compared with 23% (24/103) in Discussion PCR ribotyping PCR ribotyping was performed as previously described [12] and, altogether, a subset of 307 of 606 isolates (16 (1993), This study provides a comprehensive description of the susceptibility to 17 antimicrobials, including their MIC distributions, of clinical C. difficile isolates (n = 606) from
3 1106 Clinical Microbiology and Infection, Volume 16 Number 8, August 2010 CMI TABLE 1. Susceptibility to metronidazole, vancomycin, teicoplanin and fusidic acid of Clostridium difficile isolates from primary C. difficile infection (CDI) patients in in Örebro County, Sweden Boxed numbers 1993 to These C. difficile isolates were sampled consecutively every second to fourth year from primary CDI patients in Örebro County, Sweden, and this made possible identification of any imported or local emergence of resistance. All 606 isolates were susceptible ( 4 mg/l, to metronidazole, as has been found in previous studies [7,13], although the highest MICs (2 mg/l) observed could cause some therapeutic concern, considering the low gut concentrations of metronidazole [14]. Both intermediate and/or high-level resistance to metronidazole and vancomycin have been described in vitro [15], but the clinical relevance in vivo remains unclear [10]. All but three of our isolates displayed vancomycin MICs of 2 mg/l. These three isolates were all from CDI episodes in the same individual subjected to haemodialysis and long-term intravenous vancomycin therapy for recurrent Staphylococcus aureus septicaemia. Treatment of additional pneumonia and urinary tract infection precipitated subsequent multiple CDI episodes. Interestingly, all three episodes were caused by PCR ribotype 002 (data not shown). The other glycopeptide tested, teicoplanin, had high activity, with an MIC 90 of mg/l. Notably, the two isolates from 1999 with the highest teicoplanin MIC (0.5 mg/l; Table 1) were of the same PCR ribotype (002) as isolates that displayed elevated MICs of vancomycin. Fusidic acid has been proven to be comparable to metronidazole in clinical efficacy in a few clinically controlled CDI trials [16,17]. C. difficile isolates are mostly susceptible to fusidic acid [18], as was also confirmed in the present study. Only 0.7% of the isolates showed high-level resistance, and all of these were from patients treated with fusidic acid prior to the onset of CDI (data not shown). Accordingly, like other bacteria, such as the staphylococci, C. difficile may rapidly develop high-level fusidic acid resistance after treatment [19]. Cephalosporins are known to have a high propensity to precipitate CDI [20] and, as expected, cefuroxime had no activity against the C. difficile isolates tested. However, penicillin V, which is known to affect Gram-positive anaerobes, showed an MIC 90 of 8 mg/l, similar to the 4 mg/l found by Tyrell et al. [21]. Fifteen isolates from 1993 to 1999 displayed MICs of >8 mg/l; four of these were highly resistant (MIC 128 mg/l), which could suggest the presence of a b- lactamase. The MIC 90 was higher (32 mg/l) in the case of the b-lactam piperacillin, but a general trend of fewer resistant isolates in later years (2% of isolates with MICs of
4 CMI Norén et al. Antimicrobial resistance of C. difficile in Sweden 1107 TABLE 2. Susceptibility to erythromycin, clindamycin, rifampicin, penicillin V, piperacillin and cefuroxime in Clostridium difficile isolates from primary C. difficile infection patients in in Örebro County, Sweden Boxed numbers >16 mg/l in vs. 33% for ) was noted (Table 2). This observation remains unexplained, since the usage of this antibiotic has not decreased accordingly. In 2004 and 2007, however, 81% (22/27) of the piperacillinresistant (MIC 16 mg/l) C. difficile isolates were of PCR ribotype 012 (p )(data not shown), representing the epidemic genotype in the geographical area studied. Significant outbreaks caused by C. difficile isolates that are highly resistant to clindamycin (MIC >256 mg/l) are well known [22], but only 10% of Swedish isolates are highly resistant under endemic conditions [14]. Considering only highly resistant isolates, we identified a peak proportion of clindamycin resistance of 41% in 1997, and these clindamycin-resistant isolates represented 32 of 36 of the erythromycin-resistant isolates (36%) and all of the rifampicin-resistant isolates (38%). This association of clindamycin, erythromycin and rifampicin resistance was found consistently over the years examined, and such isolates were found in 1999, 2004 and 2007 to be of PCR ribotype 012 in 89%, 69% and 79% of cases, respectively, indicating a clonal relationship (data not shown). Furthermore, we found this clindamycin erythromycin rifampicin-resistant PCR ribotype 012 strain to be also resistant to piperacillin, tetracycline and moxifloxacin (Table 3). Similar multiresistance has been described in Germany [23], although the relationship with PCR ribotype 012 is not known. In the search for new CDI treatment regimens, rifampicinlike agents such as rifalazil have been tested, but recent
5 1108 Clinical Microbiology and Infection, Volume 16 Number 8, August 2010 CMI TABLE 3. Susceptibility to tetracycline, tigecycline, daptomycin, linezolid, moxifloxacin, levofloxacin and ciprofloxacin in Clostridium difficile isolates from primary C. difficile infection patients in in Örebro County, Sweden Boxed numbers reports of highly resistant isolates (MIC >256 mg/l) are discouraging [24]. In the present study, the C. difficile isolates were either highly susceptible or, in the case of as many as 38%, highly resistant to rifampicin (Table 2). This is similar to the findings in some more epidemic settings, e.g. in Bristol, UK [25], but different from the situations encountered in other places [26]. Perhaps resistance may explain the poor results in the past studies that have used rifampicin for CDI treatment [27]. Fluoroquinolones have selective activity on the microflora of the colon, and both selection of pre-existing and new resistant mutants and activity against other anaerobic bacteria will increase the risk of CDI. The risk thought to be associated with moxifloxacin usage has been attributed to its extended anti-anaerobe spectrum and, thus, its propensity to disrupt this major part of the colonic flora [28]. Perhaps decades of ciprofloxacin use have contributed to the selection of fluoroquinolone resistance mutations in colonizing C. difficile strains [29]. The possibility is supported by our findings of 2% of moxifloxacin-resistant isolates as early as 1993, before the drug was marketed (data not shown), alongside 100% ciprofloxacin and levofloxacin resistance. Moreover, the 4 23% increase in moxifloxacin resistance among isolates from 2004 to 2007 is explained mainly by the spread of the multiresistant PCR ribotype 012 (Table 3). The mechanism of moxifloxacin resistance in these PCR ribotype 012 isolates and the cause of their increase in later years is unknown. As moxifloxacin is rarely used in Sweden, the increase in this ribotype could instead be related to co-selection by other antibiotics or increased virulence of the actual epidemic strain. Notably, none of the moxafloxacin-resistant isolates belonged to the current epidemic PCR ribotype 027, which has so far been rarely found in Sweden [3]. In conclusion, the present study confirms the reassuring susceptibility data for metronidazole regarding clinical C. difficile isolates, and supports its further use as a first-line therapeutic agent in treating CDI. The unique 15-year timespan of consecutive sampling of isolates from a well-defined geographical area enabled us to detect variations of multiresistance in C. difficile and unsuspected elevations of MICs of common b-lactams agents such as penicillin V and piperacillin. Finally, monitoring of fluctuating susceptibility data over
6 CMI Norén et al. Antimicrobial resistance of C. difficile in Sweden 1109 TABLE 4. Range, MIC 50, MIC 90 and geometric mean of MIC of 17 antimicrobial agents for toxigenic Clostridium difficile isolates from primary C. difficile infection patients in in Örebro County, Sweden MIC (mg/l) Antimicrobial agent Isolates tested Range MIC 50 MIC 90 mean a Geometric Metronidazole b 606 < Vancomycin Teicoplanin 401 < Fusidic acid to > Erythromycin to > > Clindamycin to > > Rifampicin 606 <0.016 to >256 <0.016 > Penicillin V to > Piperacillin b to > Cefuroxime 401 >256 >256 >256 >256 Tetracycline to > > Tigecycline 205 < < Daptomycin Linezolid Moxifloxacin to > > Levofloxacin 205 >32 >32 >32 >32 Ciprofloxacin 606 >32 >32 >32 >32 a MIC values <0.016, >32 and >256 mg/l were approximated to 0.016, 32 and 256 mg/l. b All isolates were susceptible to metronidazole (MIC <4.0 mg/l), and 106 of 606 (17%) of isolates were resistant to piperacillin (MIC >16.0 mg/l) according to the only established breakpoints by the European Committee on Antimicrobial Susceptibility Testing (EUCAST; time identified a high prevalence of the local multiresistant epidemic strain, PCR ribotype 012, which was responsible for the 2007 emergence of resistance to moxifloxacin. This again emphasizes the importance of monitoring antimicrobial susceptibility, and also of genotyping C. difficile isolates, when evaluating any change in antimicrobial susceptibility [30]. Transparency Declaration This study was supported by grants from the Örebro County Council Research Committee, Örebro University Hospital, Örebro, Sweden. No conflicts of interest to declare among authors. References 1. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12 (suppl 6): McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: Åkerlund T, Persson I, Unemo M et al. Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol 2008; 46: Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to Antimicrob Agents Chemother 2007; 51: John R, Brazier JS. Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect 2005; 61: Drummond LJ, McCoubrey J, Smith DG, Starr JM, Poxton IR. Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J Med Microbiol 2003; 52: Johnson S, Sanchez JL, Gerding DN. Metronidazole resistance in Clostridium difficile. Clin Infect Dis 2000; 31: Baines SD, O Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: Norén T, Åkerlund T, Bäck E et al. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol 2004; 42: Aspevall O, Lundberg A, Burman LG, Åkerlund T, Svenungsson B. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother 2006; 50: Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46: Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004; 54: Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic
7 1110 Clinical Microbiology and Infection, Volume 16 Number 8, August 2010 CMI acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: Leroi MJ, Siarakas S, Gottlieb T. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid. Eur J Clin Microbiol Infect Dis 2002; 21: Norén T, Wullt M, Åkerlund T, Bäck E, Odenholt I, Burman LG. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob Agents Chemother 2006; 50: Thomas C, Riley TV. Restriction of third generation cephalosporin use reduces the incidence of Clostridium difficile-associated diarrhoea in hospitalised patients. Commun Dis Intell 2003; 27 (suppl): S28 S Tyrrell KL, Citron DM, Warren YA, Fernandez HT, Merriam CV, Goldstein EJ. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. Antimicrob Agents Chemother 2006; 50: Johnson S, Samore MH, Farrow KA et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999; 341: Ackermann G, Degner A, Cohen SH, Silva J, Jr., Rodloff AC. Prevalence and association of macrolide-lincosamide-streptogramin B (MLS (B)) resistance with resistance to Moxifloxacin in Clostridium difficile. J Antimicrob Chemother 2003; 51: Curry SR, Marsh JW, Shutt KA et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009; 48: Bendle JS, James PA, Bennett PM, Avison MB, Macgowan AP, Al-Shafi KM. Resistance determinants in strains of Clostridium difficile from two geographically distinct populations. Int J Antimicrob Agents 2004; 24: Bishara J, Bloch Y, Garty M, Behor J, Samra Z. Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis 2006; 54: Lagrotteria D, Holmes S, Smieja M, Smaill F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43: Deshpande A, Pant C, Jain A, Fraser TG, Rolston DD. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr Med Res Opin 2008; 24: Samore MH, Venkataraman L, DeGirolami PC et al. Genotypic and phenotypic analysis of Clostridium difficile correlated with previous antibiotic exposure. Microb Drug Resist 2006; 12: Wilcox MH, Fawley W, Freeman J, Brayson J. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2000; 46:
Should we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationAAC Revised. Activity of a Novel Cyclic Lipopeptide, CB-183,315 Against Resistant Clostridium difficile
AAC Accepts, published online ahead of print on 5 March 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.06257-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 AAC06257-11
More informationOverview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases
Overview of C. difficile infections Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Conflicts of Interest I have no financial conflicts of interest related to this topic and presentation.
More informationIn vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain
J Antimicrob Chemother 2015; 70: 2311 2315 doi:10.1093/jac/dkv092 Advance Access publication 15 April 2015 In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationAntimicrobial susceptibility testing of Clostridium difficile using EUCAST epidemiological cut-off values and disk diffusion correlates
ORIGINAL ARTICLE BACTERIOLOGY Antimicrobial susceptibility testing of Clostridium difficile using EUCAST epidemiological cut-off values and disk diffusion correlates L. T. Erikstrup 1,2, T. K. L. Danielsen
More informationSESSION XVI NEW ANTIBIOTICS
SESSION XVI NEW ANTIBIOTICS New Antibiotics to Treat Anaerobic Infections 2 Goldstein, E.J.C.;* Citron, D.M. Antibiotic Pharmacodynamics 3 Stein, G.E.* Targeting Selenium Metabolism in Stickland Fermentors:
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More information(c) 2016, Freeman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
This is a repository copy of In vitro activities of MCB3681 and 8 comparators against Clostridium difficile isolates with known ribotypes and diverse geographical spread. White Rose Research Online URL
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationMarlene Wullt* and Inga Odenholt. Department of Infectious Diseases, University Hospital, Malmö, Sweden
Journal of Antimicrobial Chemotherapy (2004) 54, 211 216 DOI: 10.1093/jac/dkh278 Advance Access publication 26 May 2004 A double-blind randomized controlled trial of fusidic acid and metronidazole for
More informationon February 12, 2018 by guest
AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationClostridium difficile
Clostridium difficile A Challenge in Long-Term Care Andrew E. Simor, MD, FRCPC Sunnybrook Health Sciences Centre University of Toronto Hosted by Paul Webber paul@webbertraining.com Objectives to understand
More informationWhat is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups. by author. Gunnar Kahlmeter, Derek Brown
What is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups Gunnar Kahlmeter, Derek Brown Izmir, February 2011 Anaerobes subcommittee EUCAST Subcommittee on breakpoints
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationClostridium difficile Infection Prevention. Basics of Infection Prevention 2-Day Mini-Course 2012
Clostridium difficile Infection Prevention Basics of Infection Prevention 2-Day Mini-Course 2012 2 Objectives Describe the etiology and epidemiology of C. difficile infection (CDI) Review evidence-based
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationA Norazah, M D*, V K E Lim, FRCPath**, MY Rohani, MPath*, A G M Kamel, MD**,
I ORIGINAL ARTICLE In-Vitro Activity of Quinupristin/ Dalfopristin, Levofloxacin and Moxifloxacin Against Fusidic Acid and Rifampicin-Resistant Strains of Methicillin Resistant Staphylococcus Aureus (MRSA)
More informationORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA
ORIGINAL ARTICLE In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 2001 M. E. Jones 1, R. S. Blosser-Middleton
More informationComparison of Supplemented Brucella Agar and Modified Clostridium difficile Agar for Antimicrobial Susceptibility Testing of Clostridium difficile
Original Article Clinical Microbiology Ann Lab Med 14;34:439-445 http://dx.doi.org/.3343/alm.14.34.6.439 ISSN 2234-386 eissn 2234-3814 Comparison of Supplemented Brucella Agar and Modified Clostridium
More informationMoxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece
Journal of Antimicrobial Chemotherapy (2008) 62, 137 141 doi:10.1093/jac/dkn134 Advance Access publication 1 April 2008 Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in
More informationORIGINAL ARTICLE /j x. University, Göteborg, Sweden
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01002.x Antibiotic resistance in Staphylococcus aureus colonising the intestines of Swedish infants E. Lindberg 1,2, I. Adlerberth 1 and A. E. Wold 1 1 Department
More informationReply to Fabre et. al
Reply to Fabre et. al L. Clifford McDonald, 1 Stuart Johnson, 2,3 Johan S. Bakken, 4 Kevin W. Garey, 5 Ciaran Kelly, 6 Dale N. Gerding, 2 1 Centers for Disease Control and Prevention, Atlanta, Georgia;
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationAntibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
Antimicrobial susceptibility of Shigella, 2015 and 2016 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationVancomycin for the Treatment of Clostridium difficile Infection: For Whom Is This Expensive Bullet Really Magic?
IDSA LECTURE Vancomycin for the Treatment of Clostridium difficile Infection: For Whom Is This Expensive Bullet Really Magic? Jacques Pepin Department of Microbiology and Infectious Diseases, University
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationImpact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis
ORIGINAL ARTICLE EPIDEMIOLOGY Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis J. Price 1, E. Cheek 2,
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationPILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996
PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 996 November 996 by Maggie Brett Antibiotic Reference Laboratory ESR Communicable Disease Centre Porirua CONTENTS Page SUMMARY
More informationSurgical prophylaxis for Gram +ve & Gram ve infection
Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationMicrobiology : antimicrobial drugs. Sheet 11. Ali abualhija
Microbiology : antimicrobial drugs Sheet 11 Ali abualhija return to our topic antimicrobial drugs, we have finished major group of antimicrobial drugs which associated with inhibition of protein synthesis
More informationInt.J.Curr.Microbiol.App.Sci (2018) 7(8):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 08 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.708.378
More informationAnaerobe bakterier og resistens. Ulrik Stenz Justesen Klinisk Mikrobiologisk Afdeling Odense Universitetshospital Odense, Denmark
Anaerobe bakterier og resistens Ulrik Stenz Justesen Klinisk Mikrobiologisk Afdeling Odense Universitetshospital Odense, Denmark Programme anaerobic bacteria Carbapenem and metronidazole resistance New
More informationOriginal Article. Suwanna Trakulsomboon, Ph.D., Visanu Thamlikitkul, M.D.
Original Article Vol. 25 No. 2 In vitro activity of daptomycin against MRSA:Trakulsomboon S & Thamlikitkul V. 57 In Vitro Activity of Daptomycin against Methicillin- Resistant Staphylococcus aureus (MRSA)
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationAssociation of tcda+/tcdb+ Clostridium difficile Genotype with Emergence of Multidrug-Resistant Strains Conferring Metronidazole Resistant Phenotype
Iranian Biomedical Journal 9 (3): 43-4 (July 5).75/ibj.5.3.3 Association of tcda+/tcdb+ Clostridium difficile Genotype with Emergence of Multidrug-Resistant Strains Conferring Metronidazole Resistant Phenotype
More informationClostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU
Clostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU Disclosures I am not Tom Riley The Fidaxomicin guys brought me dinner once Outline ASID/AICA position
More informationRESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN
RESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN Hussein Azzam Bataineh 1 ABSTRACT Background: Vancomycin has been widely used in the treatment of infections caused by Methicillin-Resistant
More informationHealthcare-associated Infections Annual Report December 2018
December 2018 Healthcare-associated Infections Annual Report 2011-2017 TABLE OF CONTENTS INTRODUCTION... 1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS... 2 MRSA SURVEILLANCE... 3 CLOSTRIDIUM
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationClostridium difficile infection: The Present and the Future
Clostridium difficile infection: The Present and the Future Carlos E. Figueroa Castro, MD Assistant Professor, Division of Infectious Diseases Medical College of Wisconsin November 2014 I have made this
More informationSource: Portland State University Population Research Center (
Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationGlycopeptide Resistant Enterococci (GRE) Policy IC/292/10
BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,
More informationLINEE GUIDA: VALORI E LIMITI
Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationMicrobiological Surveillance of Methicillin Resistant Staphylococcus aureus (MRSA) in Belgian Hospitals in 2003
Microbiological Surveillance of Methicillin Resistant Staphylococcus aureus (MRSA) in Belgian Hospitals in 3 Final report Olivier Denis and Marc J. Struelens Reference Laboratory for Staphylococci Department
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationTowards Rational International Antibiotic Breakpoints: Actions from the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
Towards Rational International Antibiotic Breakpoints: Actions from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) A report to ISC presented by Paul M. Tulkens representative of
More informationMolecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland
Journal of Medical Microbiology (2007), 56, 921 929 DOI 10.1099/jmm.0.47176-0 Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More information11/2/2015. Update on the Treatment of Clostridium difficile Infections. Disclosure. Objectives
Update on the Treatment of Clostridium difficile Infections Spencer H. Durham, Pharm.D.,BCPS (AQ-ID) Assistant Clinical Professor of Pharmacy Practice Auburn University Harrison School of Pharmacy Kurt
More informationIn vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains
Eur J Clin Microbiol Infect Dis (2010) 29:503 507 DOI 10.1007/s10096-010-0886-2 ARTICLE In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationMili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
More informationSheffield User Group Day October Members of the BSAC Working party on Susceptibility Testing present:
Sheffield User Group Day October 2006 Members of the BSAC Working party on Susceptibility Testing present: Trevor Winstanley Jenny Andrews Robin Howe David Livermore (Meeting Chairman) [TW] (Speaker) [JA]
More informationResistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints
...PRESENTATIONS... Resistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints Angela B. Brueggemann, MS; and Gary V. Doern, PhD Presentation Summary Streptococcus pneumoniae
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationESCMID Online Lecture Library. by author
Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which
More informationAntimicrobial Activity of Linezolid Against Gram-Positive Cocci Isolated in Brazil
BJID 2001; 5 (August) 171 Antimicrobial Activity of Linezolid Against Gram-Positive Cocci Isolated in Brazil Helio S. Sader, Ana C. Gales and Ronald N. Jones Special Clinical Microbiology Laboratory, Division
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationIncidence of hospital-acquired Clostridium difficile infection in patients at risk
Baptist Health South Florida Scholarly Commons @ Baptist Health South Florida All Publications 5-20-2016 Incidence of hospital-acquired Clostridium difficile infection in patients at risk Christine Ibarra
More informationPreventing Clostridium difficile Infection (CDI)
1 Preventing Clostridium difficile Infection (CDI) All Hands on Deck to Reduce CDI Skill Nursing Facility Conference July 28, 2017 Idamae Kennedy, MPH,BSN,RN,CIC Liaison Infection Preventionist Healthcare
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationQuality assurance of antimicrobial susceptibility testing
Quality assurance of antimicrobial susceptibility testing Derek Brown Routine quality control Repeated testing of controls in parallel with tests to ensure that the test system is performing reproducibly
More informationVolume-7, Issue-2, April-June-2016 Coden IJABFP-CAS-USA Received: 5 th Mar 2016 Revised: 11 th April 2016 Accepted: 13 th April 2016 Research article
Volume-7, Issue-2, April-June-2016 Coden IJABFP-CAS-USA Copyrights@2016 Received: 5 th Mar 2016 Revised: 11 th April 2016 Accepted: 13 th April 2016 Research article A STUDY ON ANTIBIOTIC SUSCEPTIBILITY
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationProceedings of the 19th American Academy of Veterinary Pharmacology and Therapeutics Biennial Symposium
www.ivis.org Proceedings of the 19th American Academy of Veterinary Pharmacology and Therapeutics Biennial Symposium May 17-20, 2015 Fort Collins, CO, USA Reprinted in the IVIS website with the permission
More informationStudies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India
Human Journals Research Article April 2016 Vol.:6, Issue:1 All rights are reserved by Zarine Khety et al. Studies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India Keywords: Drug
More informationClostridium difficile may be found in 1% to 3% of all
ORIGINAL ARTICLE Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients Kruti Shah, PharmD, BCPS, Leigh Ann Pass, PharmD, BCPS, Mark Cox, PharmD,
More information